Venus Medtech (Hangzhou) has signed an agreement to acquire Keystone Heart for an undisclosed sum.
The acquisition will provide Venus Medtech with access to the international rights to Keystone Heart’s TriGUARD 3 cerebral embolic protection device. The device is designed to provide complete coverage to all the three major cerebral brain regions for patients undergoing cardiac procedures.
The transaction is expected to be closed in the last quarter of 2018, subject to customary closing conditions.
Venus Medtech is a Chinese developer of interventional artificial cardiac valve systems, while Keystone Heart is an Israel-based medical device firm specialising in the development of embolic cerebral protection devices.
The acquisition will enable the Venus Medtech to establish its presence in the US and EMEA regions.
Medtronic and Mazor Robotics have entered a definitive merger agreement to acquire all the outstanding shares of the latter for $1.64bn.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Based in the US, Medtronic creates device-based medical therapies, while Mazor Robotics is an Israeli developer of medical devices used for surgical procedures in the fields of orthopaedics and neurosurgery.
The deal will enable Medtronic to expand its footprint in the area of spine surgery technologies by combining its intra-operative imaging technology with Mazor’s robotic-assisted surgery (RAS) systems.
Cancer Genetics has signed a definitive agreement to merge with Israel-based functional genomics firm NovellusDx.
The transaction is being executed through Cancer Genetics’ Israel-based subsidiary and will combine the company’s test portfolio and broad data set related to tumour biology, with NovellusDx’s proprietary technology and machine learning capabilities.
The newly formed entity will be an oncology-focused medical technology company offering advanced science and cutting-edge technology to empower oncologists and the biopharma industry.
Cancer Genetics is a US-based provider of diagnostic products in the area of oncology.